ArticleProceedings of the National Academy of Sciences of the United States of America1997
Peptide inhibition of glomerular deposition of an anti-DNA antibody.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 189 citations in OpenAlex.
- Restoring B cell intrinsic tolerance to lupus autoimmunity: a rational strategy for lupus treatment.Frontiers in immunology · 2026Review
- Novel and unique rheumatoid factors cross-react with viral epitopes in COVID-19.Journal of autoimmunity · 2024Article
- Peptide-based immunotherapy in lupus: Where are we now?Rheumatology and immunology research · 2023Review
- Mouse models, antibodies, and neuroimaging: Current knowledge and future perspectives in neuropsychiatric systemic lupus erythematosus (NPSLE).Frontiers in psychiatry · 2023Review
- Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE): Can They Be Used as Biomarkers for the Differential Diagnosis of This Disease?Clinical reviews in allergy & immunology · 2022Review
- Autoantibody:Autoantigen Competitor Decoys: Application to Cardiac Phenotypes.Frontiers in immunology · 2022Review
- The expansion of activated naive DNA autoreactive B cells and its association with disease activity in systemic lupus erythematosus patients.Arthritis research & therapy · 2021Article
- Meant to B: B cells as a therapeutic target in systemic lupus erythematosus.The Journal of clinical investigation · 2021Review
- Expanded Autoantibody Profiles for Subsetting of Native American, African American, and European American Patients With Systemic Lupus Erythematosus.ACR open rheumatology · 2020Article
- Using the Mouse to Model Human Diseases: Cognitive Impairment in Systemic Lupus Erythematosus.The Journal of rheumatology · 2020Article
- HOT or not: examining the basis of high-occupancy target regions.Nucleic acids research · 2019Article
- Assessing cognitive impairment in SLE: examining relationships between resting glucose metabolism and anti-NMDAR antibodies with navigational performance.Lupus science & medicine · 2019Article
- Peptide ligand-based ELISA reagents for antibody detection.Analytical biochemistry · 2018Article
- Antibody repertoire analysis in polygenic autoimmune diseases.Immunology · 2018Review
- DNA-Mediated Interferon Signature Induction by SLE Serum Occurs in Monocytes Through Two Pathways: A Mechanism to Inhibit Both Pathways.Frontiers in immunology · 2018Article
- Antigen-specific immunotherapies in rheumatic diseases.Nature reviews. Rheumatology · 2017Review
- The Role of Brain-Reactive Autoantibodies in Brain Pathology and Cognitive Impairment.Frontiers in immunology · 2017Review
- DNA-reactive B cells in lupus.Current opinion in immunology · 2016Review
- Amending HIV Drugs: A Novel Small-Molecule Approach To Target Lupus Anti-DNA Antibodies.Journal of medicinal chemistry · 2016Article
- Mapping an epitope in EBNA-1 that is recognized by monoclonal antibodies to EBNA-1 that cross-react with dsDNA.Immunity, inflammation and disease · 2016Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Antibodies to double-stranded DNA are pathognomonic of systemic lupus erythematosus and deposit in the kidneys of lupus patients to cause glomerulonephritis. Recent data suggest that a significant proportion of anti-DNA antibodies may cross-react with renal antigens and be sequestered in the kidney by virtue of this cross-reactivity. If this is true, antigenic competition for pathogenic antibodies might prevent their deposition in kidneys and the ensuing tissue damage. To generate surrogate antigens that could be used for this purpose, we have used peptide display phage libraries to identify peptides that react with R4A, a pathogenic mouse monoclonal anti-DNA antibody that deposits in glomeruli. We have demonstrated that the peptides bind in or near the double-stranded DNA binding site. Furthermore, the peptides are bound preferentially by the R4A antibody as compared with two closely related antibodies derived from it, one of which deposits in renal tubules and one of which displays no renal pathogenicity. Administration of one of these peptides in a soluble form protects mice from renal deposition of the R4A anti-DNA antibody in vivo. This represents a new therapeutic approach in systemic lupus erythematosus that focuses on protecting target organs from antibody mediated injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.